Insider trade

CEO purchased ~$753K of ELV shares in the open market

Traded Jul 17, 2026 · Filed Jul 17, 2026

~$753K
Reported value · 2,045 sh @ $368.25: 172K
Holds after · shares reported: +2.3%
stock since the trade · S&P 500 +2.8%, $373.11 → $381.67 on Oct 1

Why it stands out

The boss of Elevance Health spent $753K of their very own money to buy Elevance Health shares. 1 other person at Elevance Health bought some too, in the same month.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Jul 17, 2026
Reporting period: Not applicable
Filed with the SEC: Jul 17, 2026

CEO$500K–$1MHoldings +1%2 insiders bought in 30d

Context

Classification

open market purchase

Code P — open-market or private purchase

Absolute commitment

~$753,071

Shares × reported transaction price

Size band

$500K–$1M

Ownership change

+1.2%

Purchase shares ÷ estimated pre-transaction holdings, from the filing

Rarity

Not enough history to judge

Confirmed open-market purchases by the same insider in the available history

Cluster activity

2 distinct insiders in 30 days

Distinct insiders at the same issuer with confirmed open-market purchases

Size vs CEO pay

This purchase equals about 3.3% of the CEO's reported total pay for fiscal 2025 ($22.6M)

Purchase value ÷ the CEO's total from the Summary Compensation Table, as tagged in the pay versus performance table of the company's proxy statement (DEF 14A), filed 2026-03-27. The proxy names Gail Boudreaux as CEO for that year. A size comparison, not a judgement

Timing vs results

2 days after results of Jul 15, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $373.11 on Jul 17, 2026, 36% above its 52-week low and 13% below its high, after a 5% drop over the previous 30 trading days

52-week range $274.66 (Aug 1, 2025) to $426.79 (Jul 14, 2026), 65% of the way up, from 251 adjusted closes. 30 trading days earlier: $391.27 on Jun 3, 2026. Describes the past only, not a forecast

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

Securities lawsuit open at the trade date

A securities lawsuit naming the company as a defendant was filed on May 12, 2025 in the U.S. District Court, S.D. Indiana. A filing is an allegation, not a finding.

MILLER v. ELEVANCE HEALTH, INC., docket 1:25-cv-00923, via CourtListener (court records). Nature of suit 850, company named as first defendant

After it was reported

After	Stock	S&P 500	Difference
7 days	-1.0%	-0.4%	-0.6%
30 days	+4.2%	+3.6%	+0.6%

Past results only. Not a forecast.

Source receipt

Record ID: 0001287920-26-000006
Filed / recorded: Jul 17, 2026, 5:50 PM UTC
Added to OQRO: Oct 2, 2026, 12:27 PM UTC
Parser: form4-xml-v1
Data quality: Verified: identifiers matched exactly
Issuer: Elevance Health, Inc.
Issuer CIK: 1156039
Ticker: ELV
Reporting person: Gail Boudreaux
Relationship: Director, Officer
Officer title: President and CEO
Security: Common Stock
Table: Non-derivative (Table I)
Transaction date: Jul 17, 2026
Transaction code: P
Shares / units: 2,045
Price per share: $368.25
Acquired / disposed: Acquired (A)
Shares owned after: 171,976
Ownership form: Direct
Amendment: No

Footnotes from the filing

This transaction was executed in multiple purchases at prices ranging from $367.76 to $368.69. The price reported reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Around the same time

3mo ago

Congress trade

$1,001 - $15,000Reported range · official band, not an exact amount

2 different filers disclosed ELV within 90 days. Disclosed 116 days after the transaction; reported as an official range, not an exact amount.

Why it stands out Official record

Director bought3mo ago

~$366KReported value · 1,000 sh @ $366.05

A board member of Elevance Health spent $366K of their very own money to buy Elevance Health shares. 1 other person at Elevance Health bought some too, in the same month. Their pile of Elevance Health shares grew by 10%.

Why it stands out Official record

CEO bought3mo ago

~$249KReported value · 680 sh @ $366.41

The boss of Elevance Health spent $249K of their very own money to buy Elevance Health shares. 1 other person at Elevance Health bought some too, in the same month.

Why it stands out Official record